What 5 Analyst Ratings Have To Say About RxSight
RxSight (NASDAQ:RXST) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 0 | 4 | 0 | 0 |
| Last 30D | 1 | 0 | 2 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 1 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $10.6, a high estimate of $13.00, and a low estimate of $9.00. This upward trend is apparent, with the current average reflecting a 3.92% increase from the previous average price target of $10.20.
Decoding Analyst Ratings: A Detailed Look
A clear picture of RxSight's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Danielle Antalffy | UBS | Raises | Neutral | $9.00 | $8.00 |
| Adam Maeder | Piper Sandler | Lowers | Neutral | $10.00 | $11.00 |
| David Saxon | Needham | Maintains | Buy | $13.00 | $13.00 |
| Adam Maeder | Piper Sandler | Raises | Neutral | $11.00 | $10.00 |
| Patrick Wood | Morgan Stanley | Raises | Equal-Weight | $10.00 | $9.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to RxSight. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of RxSight compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of RxSight's stock. This analysis reveals shifts in analysts' expectations over time.
To gain a panoramic view of RxSight's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on RxSight analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
All You Need to Know About RxSight
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
RxSight's Economic Impact: An Analysis
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Challenges: RxSight's revenue growth over 3M faced difficulties. As of 30 September, 2025, the company experienced a decline of approximately -14.09%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: RxSight's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -32.35%, the company may face hurdles in effective cost management.
Return on Equity (ROE): RxSight's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -3.54%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): RxSight's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -3.18%, the company may face hurdles in achieving optimal financial returns.
Debt Management: RxSight's debt-to-equity ratio is below the industry average at 0.04, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Significance of Analyst Ratings Explained
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.